Real World Study to Describe the Effectiveness and Safety of Teprotumumab Among Thyroid Eye Disease Patients

Launched by AMGEN · Jul 23, 2025

Keywords

ClinConnect Summary

This clinical trial is studying how well and how safely a medicine called teprotumumab works for people with Thyroid Eye Disease, a condition that can cause the eyes to bulge or become uncomfortable. The main goal is to see how many patients show improvement in eye bulging after receiving their last dose of the medicine through an IV (a drip into the vein).

People who might join this study are those who have already had at least one dose of teprotumumab for their Thyroid Eye Disease and have agreed to participate in the study. It’s important to note that this study is specifically for patients of Chinese ethnicity. If you join, you can expect to have your health monitored to help researchers understand how well the treatment is working and if it is safe. The study is currently looking for participants, so if you or a family member fits these criteria, you may want to talk to your doctor about this opportunity.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Receipt of at least 1 infusion of teprotumumab for treatment of the TED.
• • Obtained study specific informed consent form (ICF), if required.
• Exclusion Criteria:
• • Documentation of non-Chinese ethnicity.